Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: Implications in warfarin therapy

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 2114-2123

  Zhang, Nan ^a   Seguin, Ryan P ^b   Kunze, Kent L ^b   Zhang, Yan Yan ^a   Jeong, Hyunyoung ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; DRUG METABOLITE; NOSCAPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; WARFARIN;

ABSORPTION SPECTROSCOPY; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG HYDROXYLATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL; SPECTROSCOPY; TIMED DRUG RELEASE; ULTRAFILTRATION;

ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; NOSCAPINE; RECOMBINANT PROTEINS; WARFARIN;

EID: 84888619257     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053330     Document Type: Article

References (46)

1. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, and Joshi HC (2007) Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 60:831-839.
2. Barken I, Geller J, and Rogosnitzky M (2010) Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 30:399-401.
3. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
4. Castellan A-C, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, and Nony P; Genophar Working Group (2013) Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet 52:199-209.
5. Chougule M, Patel AR, Sachdeva P, Jackson T, and Singh M (2011a) Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer 71:271-282.
6. Chougule MB, Patel AR, Jackson T, and Singh M (2011b) Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS ONE 6:e17733.
7. Eriksson N and Wadelius M (2012) Prediction of warfarin dose: why, when and how? Pharmacogenomics 13:429-440.
8. Fang Z-Z, Krausz KW, Li F, Cheng J, Tanaka N, and Gonzalez FJ (2012) Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol 167:1271-1286.
9. Fang Z-Z, Zhang Y-Y, Ge G-B, Huo H, Liang S-C, and Yang L (2010) Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69:193-199.
10. Franklin MR (1971) The enzymic formation of methylenedioxyphenyl derivative exhibiting an isocyanide-like spectrum with reduced cytochrome P-450 in hepatic microsomes. Xenobiotica 1:581-591.
11. Fujioka Y, Kunze KL, and Isoherranen N (2012) Risk assessment of mechanism-based inactivation in drug-drug interactions. Drug Metab Dispos 40:1653-1657.
12. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
13. Grimm SW, Einolf HJ, Hall SD, He K, Lim H-K, Ling K-HJ, Lu C, Nomeir AA, Seibert E, and Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
14. Haikala V, Sothmann A, and Marvola M (1986) Comparative bioavailability and pharmacokinetics of noscapine hydrogen embonate and noscapine hydrochloride. Eur J Clin Pharmacol 31:367-369.
15. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, and Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(1, Suppl)8S-21S.
16. Hutzler JM, Balogh LM, Zientek M, Kumar V, and Tracy TS (2009) Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos 37:59-65.
17. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
18. Karlsson MO and Dahlström B (1990) Serum protein binding of noscapine: influence of a reversible hydrolysis. J Pharm Pharmacol 42:140-143.
19. Karlsson MO, Dahlström B, Eckernäs SA, Johansson M, and Alm AT (1990) Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 39:275-279.
20. Kumar V, Brundage RC, Oetting WS, Leppik IE, and Tracy TS (2008) Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36:1242-1248.
21. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975.
22. Kunze KL and Trager WF (1996) Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 24:429-435.
23. Kunze KL, Wienkers LC, Thummel KE, and Trager WF (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24:414-421.
24. Lee AYY (2009) Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 27:4895-4901.
25. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, and Cavallari LH (2012) Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther 91:660-665.
26. Madan J, Dhiman N, Sardana S, Aneja R, Chandra R, and Katyal A (2011) Long-circulating poly (ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 22:543-555.
27. Maddison J, Somogyi AA, Jensen BP, James HM, Gentgall M, and Rolan PE (2013) The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. Br J Clin Pharmacol 75:208-216.
28. Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim S-R, Kaniwa N, Katori N, Hasegawa R, Yasuda K, and Kamide K, et al. (2009) Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 37:1895-1903.
29. Mahmoudian M and Rahimi-Moghaddam P (2009) The anti-cancer activity of noscapine: a review. Recent Patents Anticancer Drug Discov 4:92-97.
30. Manno M, De Matteis F, and King LJ (1988) The mechanism of the suicidal, reductive inactivation of microsomal cytochrome P-450 by carbon tetrachloride. Biochem Pharmacol 37:1981-1990.
31. Myhr K (2009) [Noscapine and warfarin - a potentially dangerous interaction]. Tidsskr Nor Laegeforen 129:540.
32. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
33. Ohlsson S, Holm L, Myrberg O, Sundström A, and Yue Q-Y (2008) Noscapine may increase the effect of warfarin. Br J Clin Pharmacol 65:277-278.
34. Olsson B, Bolme P, Dahlström B, and Marcus C (1986) Excretion of noscapine in human breast milk. Eur J Clin Pharmacol 30:213-215.
35. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
36. Orr STM, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, and Kalgutkar AS (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55:4896-4933.
37. Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3:321-329.
38. Rahme E, Feugère G, Sirois C, Weicker S, and Ramos E (2013) Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Thromb Res 131:210-217.
39. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
40. Rosenborg S, Stenberg M, Otto S, Ostervall J, Masquelier M, Yue QY, Bertilsson L, and Eliasson E (2010) Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clin Pharmacol Ther 88:343-346.
41. Scordo MG, Melhus H, Stjernberg E, Edvardsson AM, and Wadelius M (2008) Warfarin-noscapine interaction: a series of four case reports. Ann Pharmacother 42:448-450.
42. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, and Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710.
43. Streiff MB (2009) Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 27:4889-4894.
44. Tsunoda N and Yoshimura H (1981) Metabolic fate of noscapine. III. Further studies on identification and determination of the metabolites. Xenobiotica 11:23-32.
45. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630-35637.
46. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468.